Monoclonal antibodies for non-hodgkin's lymphoma: State of the art and perspectives

Clinical and Developmental Immunology

Volumn 2010, Issue , 2010, Pages

  Nencioni, Alessio ^a   Motta, Giulia ^a   Cea, Michele ^a   Moran, Eva ^a   Carbone, Federico ^a   Augusti, Valeria ^a   Patrone, Franco ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; APOLIZUMAB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPRATUZUMAB; FLUDARABINE; GALIXIMAB; IBRITUMOMAB TIUXETAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; TOSITUMOMAB; TOSITUMOMAB I 131; VINCRISTINE; MONOCLONAL ANTIBODY;

ANGINA PECTORIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHILL; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FEVER; FOLLICULAR LYMPHOMA; HEART ARRHYTHMIA; HUMAN; HYPERSENSITIVITY REACTION; INFECTION; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LYMPHOMA CELL; MAINTENANCE THERAPY; MONOTHERAPY; NONHODGKIN LYMPHOMA; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; TUMOR LYSIS SYNDROME; ANIMAL; CLINICAL PROTOCOL; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC PROTOCOLS; COMBINED MODALITY THERAPY; HUMANS; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN;

EID: 79955092324     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2010/428253     Document Type: Review

References (130)

1. Kohler G., Milstein C., Continuous cultures of fused cells secreting antibody of predefined specificity Nature 1975 256 5517 495 497
2. Cooper N., Arnold D. M., The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases British Journal of Haematology 2010 149 1 3 13
3. Finn O. J., Cancer immunology New England Journal of Medicine 2008 358 25 2704 2715
4. Plosker G. L., Figgitt D. P., Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia Drugs 2003 63 8 803 843 (Pubitemid 36432084)
5. Demidem A., Lam T., Alas S., Hariharan K., Hanna N., Bonavida B., Chimeric anti-CD20 (idec-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs Cancer Biotherapy and Radiopharmaceuticals 1997 12 3 177 186 (Pubitemid 27349961)
6. Nadler L. M., Ritz J., Hardy R., A unique cell surface antigen identifying lymphoid malignancies of B cell origin Journal of Clinical Investigation 1981 67 1 134 140 (Pubitemid 11163165)
7. Petryk M., Grossbard M. L., Rituximab therapy of B-cell neoplasms Clinical Lymphoma 2000 1 3 186 194
8. Almasri N. M., Duque R. E., Iturraspe J., Everett E., Braylan R. C., Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia American Journal of Hematology 1992 40 4 259 263
9. Deans J. P., Li H., Polyak M. J., CD20-mediated apoptosis: signalling through lipid rafts Immunology 2002 107 2 176 182 (Pubitemid 35279043)
10. Bubien J. K., Zhou L. J., Bell P. D., Frizzell R. A., Tedder T. F., Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca conductance found constitutively in B lymphocytes Journal of Cell Biology 1993 121 5 1121 1132 (Pubitemid 23154272)
11. Walshe C. A., Beers S. A., French R. R., Chan C. H. T., Johnson P. W., Packham G. K., Glennie M. J., Cragg M. S., Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling Journal of Biological Chemistry 2008 283 25 16971 16984
12. Grillo-Lpez A. J., Hedrick E., Rashford M., Benyunes M., Rituximab: ongoing and future clinical development Seminars in Oncology 2002 29 1 105 112 (Pubitemid 34173032)
13. Onrust S. V., Lamb H. M., Balfour J. A., Rituximab Drugs 1999 58 1 79 88 (Pubitemid 29373889)
14. Glennie M. J., French R. R., Cragg M. S., Taylor R. P., Mechanisms of killing by anti-CD20 monoclonal antibodies Molecular Immunology 2007 44 16 3823 3837 (Pubitemid 47332625)
15. Teeling J. L., Mackus W. J. M., Wiegman L. J. J. M., Van Den Brakel J. H. N., Beers S. A., French R. R., Van Meerten T., Ebeling S., Vink T., Slootstra J. W., Parren P. W. H. I., Glennie M. J., Van De Winkel J. G. J., The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20 Journal of Immunology 2006 177 1 362 371 (Pubitemid 43939148)
16. Jazirehi A. R., Bonavida B., Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention Oncogene 2005 24 13 2121 2143 (Pubitemid 40516580)
17. Bonavida B., Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions Oncogene 2007 26 25 3629 3636 (Pubitemid 46842700)
18. Jazirehi A. R., Vega M. I., Chatterjee D., Goodglick L., Bonavida B., Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, BCL- down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by rituximab Cancer Research 2004 64 19 7117 7126 (Pubitemid 39331025)
19. Alas S., Bonavida B., Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs Cancer Research 2001 61 13 5137 5144 (Pubitemid 32681546)
20. Vega M. I., Jazirehi A. R., Huerta-Yepez S., Bonavida B., Rituximab-induced inhibition of YY1 and Bcl-xL expression in ramos non-Hodgkin's lymphoma cell line via inhibition of NF-{kappa}B activity: role of YY1 and Bcl-xL in Fas resistance and chemoresistance, respectively Journal of Immunology 2005 175 4 2174 2183 (Pubitemid 41113823)
21. Huerta-Yepez S., Vega M., Jazirehi A., Garban H., Hongo F., Cheng G., Bonavida B., Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF- B and inhibition of Bcl- expression Oncogene 2004 23 29 4993 5003 (Pubitemid 38938732)
22. Kheirallah S., Caron P., Gross E., Quillet-Mary A., Bertrand-Michel J., Fourni J. J., Laurent G., Bezombes C., Rituximab inhibits B-cell receptor signaling Blood 2010 115 5 985 994
23. Chen L., Monti S., Juszczynski P., Daley J., Chen W., Witzig T. E., Habermann T. M., Kutok J. L., Shipp M. A., SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma Blood 2008 111 4 2230 2237 (Pubitemid 351451430)
24. Leseux L., Hamdi S. M., Al Saati T., Capilla F., Recher C., Laurent G., Bezombes C., Syk-dependent mTOR activation in follicular lymphoma cells Blood 2006 108 13 4156 4162 (Pubitemid 44913287)
25. Young R. M., Hardy I. R., Clarke R. L., Lundy N., Pine P., Turner B. C., Potter T. A., Refaeli Y., Mouse models of non-hodgkin lymphoma reveal Syk as an important therapeutic target Blood 2009 113 11 2508 2516
26. Smith M. R., Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene 2003 22 47 7359 7368
27. Armitage J. O., How I treat patients with diffuse large B-cell lymphoma Blood 2007 110 1 29 36 (Pubitemid 47026815)
28. Marcus R., Imrie K., Solal-Celigny P., Catalano J. V., Dmoszynska A., Raposo J. C., Offner F. C., Gomez-Codina J., Belch A., Cunningham D., Wassner-Fritsch E., Stein G., Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma Journal of Clinical Oncology 2008 26 28 4579 4586
29. Hiddemann W., Kneba M., Dreyling M., Schmitz N., Lengfelder E., Schmits R., Reiser M., Metzner B., Harder H., Hegewisch-Becker S., Fischer T., Kropff M., Reis H.-E., Freund M., Wrmann B., Fuchs R., Planker M., Schimke J., Eimermacher H., Trmper L., Aldaoud A., Parwaresch R., Unterhalt M., Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group Blood 2005 106 12 3725 3732 (Pubitemid 41742196)
30. Van Oers M. H. J., Klasa R., Marcus R. E., Wolf M., Kimby E., Gascoyne R. D., Jack A., Van't Veer M., Vranovsky A., Holte H., Van Glabbeke M., Teodorovic I., Rozewicz C., Hagenbeek A., Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial Blood 2006 108 10 3295 3301 (Pubitemid 44794222)
31. Forstpointner R., Unterhalt M., Dreyling M., Bck H.-P., Repp R., Wandt H., Pott C., Seymour J. F., Metzner B., Hnel A., Lehmann T., Hartmann F., Einsele H., Hiddemann W., Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG) Blood 2006 108 13 4003 4008 (Pubitemid 44920177)
32. Herold M., Haas A., Srock S., Neser S., Al-Ali K. H., Neubauer A., Dlken G., Naumann R., Knauf W., Freund M., Rohrberg R., Hffken K., Franke A., Ittel T., Kettner E., Haak U., Mey U., Klinkenstein C., Amann M., Von Grnhagen U., Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German study group hematology and oncology study Journal of Clinical Oncology 2007 25 15 1986 1992 (Pubitemid 46972781)
33. Maloney D. G., Grillo-Lpez A. J., White C. A., Bodkin D., Schilder R. J., Neidhart J. A., Janakiraman N., Foon K. A., Liles T. M., Dallaire B. K., Wey K., Royston I., Davis T., Levy R., IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 1997 90 6 2188 2195 (Pubitemid 27392702)
34. Feuring-Buske M., Kneba M., Unterhalt M., Engert A., Gramatzki M., Hiller E., Trumper L., Brugger W., Ostermann H., Atzpodien J., Hallek M., Aulitzky E., Hiddemann W., IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German low-grade lymphoma study group Annals of Hematology 2000 79 9 493 500
35. McLaughlin P., Grillo-Lpez A. J., Link B. K., Levy R., Czuczman M. S., Williams M. E., Heyman M. R., Bence-Bruckler I., White C. A., Cabanillas F., Jain V., Ho A. D., Lister J., Wey K., Shen D., Dallaire B. K., Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program Journal of Clinical Oncology 1998 16 8 2825 2833 (Pubitemid 28363048)
36. Coiffier B., Lepage E., Brire J., Herbrecht R., Tilly H., Bouabdallah R., Morel P., Van Den Neste E., Salles G., Gaulard P., Reyes F., Lederlin P., Gisselbrecht C., Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large-B-cell lymphoma New England Journal of Medicine 2002 346 4 235 242 (Pubitemid 34438862)
37. Pfreundschuh M., Trmper L., sterborg A., Pettengell R., Trneny M., Imrie K., Ma D., Gill D., Walewski J., Zinzani P. L., Stahel R., Kvaloy S., Shpilberg O., Jaeger U., Hansen M., Lehtinen T., Lpez-Guillermo A., Corrado C., Scheliga A., Milpied N., Mendila M., Rashford M., Kuhnt E., Loeffler M., CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncology 2006 7 5 379 391
38. Habermann T. M., Weller E. A., Morrison V. A., Gascoyne R. D., Cassileth P. A., Cohn J. B., Dakhil S. R., Woda B., Fisher R. I., Peterson B. A., Horning S. J., Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma Journal of Clinical Oncology 2006 24 19 3121 3127 (Pubitemid 46638950)
39. Lenz G., Dreyling M., Hoster E., Wrmann B., Dhrsen U., Metzner B., Eimermacher H., Neubauer A., Wandt H., Steinhauer H., Martin S., Heidemann E., Aldaoud A., Parwaresch R., Hasford J., Unterhalt M., Hiddemann W., Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantiy improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) Journal of Clinical Oncology 2005 23 9 1984 1992 (Pubitemid 46211378)
40. Robak T., Dmoszynska A., Solal-Cligny P., Warzocha K., Loscertales J., Catalano J., Afanasiev B. V., Larratt L., Geisler C. H., Montillo M., Zyuzgin I., Ganly P. S., Dartigeas C., Rosta A., Maurer J., Mendila M., Saville M. W., Valente N., Wenger M. K., Moiseev S. I., Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia Journal of Clinical Oncology 2010 28 10 1756 1765
41. CLL8- German CLL Study Group
42. Kimby E., Bjorkholm M., Gahrton G., Glimelius B., Hagberg H., Johansson B., Johansson H., Juliusson G., Jarnmark M., Lofvenberg E., Killander A., Lerner R., Lindemalm C., Petersson U., Robert K. H., Simonsson B., Stalfelt A. M., Sundstrom C., Svedmyr E., Chlorambucil/prednisone vs. CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden Annals of Oncology 1994 5 2 67 71 (Pubitemid 24061323)
43. Czuczman M. S., Weaver R., Alkuzweny B., Berlfein J., Grillo-Lpez A. J., Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up Journal of Clinical Oncology 2004 22 23 4659 4664 (Pubitemid 41185080)
44. Czuczman M. S., Koryzna A., Mohr A., Stewart C., Donohue K., Blumenson L., Bernstein Z. P., McCarthy P., Alam A., Hernandez-Ilizaliturri F., Skipper M., Brown K., Chanan-Khan A., Klippenstein D., Loud P., Rock M. K., Benyunes M., Grillo-Lopez A., Bernstein S. H., Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma Journal of Clinical Oncology 2005 23 4 694 704 (Pubitemid 46224168)
45. Hiddemann W., Buske C., Dreyling M., Weigert O., Lenz G., Forstpointner R., Nickenig C., Unterhalt M., Treatment strategies in follicular lymphomas: current status and future perspectives Journal of Clinical Oncology 2005 23 26 6394 6399 (Pubitemid 46222239)
46. Domingo-Domenech E., Gonzlez-Borco E., Estany C., Sureda A., Besalduch J., De Sevilla A. F., Combined treatment with anti CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas Haematologica 2002 87 11 1229 1230 (Pubitemid 35397786)
47. Davis T. A., Grillo-Lopez A. J., White C. A., McLaughlin P., Czuczman M. S., Link B. K., Maloney D. G., Weaver R. L., Rosenberg J., Levy R., Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment Journal of Clinical Oncology 2000 18 17 3135 3143
48. Davis T. A., White C. A., Grillo-Lpez A. J., Velsquez W. S., Link B., Maloney D. G., Dillman R. O., Williams M. E., Mohrbacher A., Weaver R., Dowden S., Levy R., Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab Journal of Clinical Oncology 1999 17 6 1851 1857 (Pubitemid 29269257)
49. Lamanna N., Jurcic J. G., Noy A., Maslak P., Gencarelli A. N., Panageas K. S., Heaney M. L., Brentjens R. J., Golde D. W., Scheinberg D. A., Zelenetz A. D., Weiss M. A., Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses Journal of Clinical Oncology 2009 27 4 491 497
50. Ahmadi T., Schuster S. J., Variations on the fludarabine, cyclophosphamide, and rituximab combination in chronic lymphocytic leukemia therapy: what have we learned? Journal of Clinical Oncology 2009 27 4 479 480
51. Kunkel L., Wong A., Maneatis T., Nickas J., Brown T., Grillo-Lpez A., Benyunes M., Grobman B., Dillman R. O., Optimizing the use of rituximab for treatment of B-cell non-Hodgkin's lymphoma: a benefit-risk update Seminars in Oncology 2000 27 6 53 61 (Pubitemid 32166264)
52. Bedognetti D., Zoppoli G., Massucco C., Patients treated with rituximab-containing immunochemotherapy have a significant and prolonged lack of humoral response to influenza vaccine associated with a persistent depletion of b memory cells Blood (ASH Annual Meeting Abstracts) November 2009
53. Cheson B. D., Leonard J. P., Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma New England Journal of Medicine 2008 359 6 613 626
54. Beers S. A., French R. R., Chan H. T. C., Lim S. H., Jarrett T. C., Vidal R. M., Wijayaweera S. S., Dixon S. V., Kim H., Cox K. L., Kerr J. P., Johnston D. A., Johnson P. W.M., Verbeek J. S., Glennie M. J., Cragg M. S., Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection Blood 2010 115 25 5191 5201
55. Wang S. Y., Veeramani S., Racila E., Cagley J., Fritzinger D. C., Vogel C. W., St John W., Weiner G. J., Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model Blood 2009 114 26 5322 5330
56. Rambaldi A., Lazzari M., Manzoni C., Carlotti E., Arcaini L., Baccarani M., Barbui T., Bernasconi C., Dastoli G., Fuga G., Gamba E., Gargantini L., Gattei V., Lauria F., Lazzarino M., Mandelli F., Morra E., Pulsoni A., Ribersani M., Rossi-Ferrini P. L., Rupolo M., Tura S., Zagonel V., Zaja F., Zinzani P., Reato G., Foa R., Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma Blood 2002 99 3 856 862 (Pubitemid 34525546)
57. Price C. G. A., Meerabux J., Murtagh S., Cotter F. E., Rohatiner A. Z. S., Young B. D., Lister T. A., The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma Journal of Clinical Oncology 1991 9 9 1527 1532
58. Limpens J., Stad R., Vos C., De Vlaam C., De Jong D., Van Ommen-G. J. B., Schuuring E., Kluin P. M., Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals Blood 1995 85 9 2528 2536
59. van Oers M. H., Tnnissen E., Van Glabbeke M., Giurgea L., Jansen J. H., Klasa R., Marcus R. E., Wolf M., Kimby E., Vranovsky A., Holte H., Hagenbeek A., van der Reijden B. A., BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study Journal of Clinical Oncology 2010 28 13 2246 2252
60. Mounier N., Briere J., Gisselbrecht C., Emile J. F., Lederlin P., Sebban C., Berger F., Bosly A., Morel P., Tilly H., Bouabdallah R., Reyes F., Gaulard P., Coiffier B., Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) Blood 2003 101 11 4279 4284 (Pubitemid 36857789)
61. Mounier N., Briere J., Gisselbrecht C., Reyes F., Gaulard P., Coiffier B., Estimating the impact of rituximab on bcl-2-associated resistance to CHOP in elderly patients with diffuse large B-cell lymphoma Haematologica 2006 91 5 715 716 (Pubitemid 43799481)
62. Kewalramani T., Zelenetz A. D., Hedrick E. E., Donnelly G. B., Hunte S., Priovolos A. C., Qin J., Lyons N. C., Yahalom J., Nimer S. D., Moskowitz C. H., High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis Blood 2000 96 7 2399 2404
63. Haioun C., Lepage E., Gisselbrecht C., Salles G., Coiffier B., Brice P., Bosly A., Morel P., Nouvel C., Tilly H., Lederlin P., Sebban C., Briere J., Gaulard P., Reyes F., Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocola groupe d'etude des lymphomes de l'adulte study Journal of Clinical Oncology 2000 18 16 3025 3030 (Pubitemid 30644128)
64. Nademanee A., Forman S. J., Role of Hematopoietic Stem Cell Transplantation for Advanced-Stage Diffuse Large Cell B-Cell Lymphoma-B Seminars in Hematology 2006 43 4 240 250 (Pubitemid 44486318)
65. Berinstein N. L., Principles of maintenance therapy Leukemia Research 2006 30 1 S3 S10
66. Hainsworth J. D., Litchy S., Burris H. A., Scullin D. C., Corso S. W., Yardley D. A., Morrissey L., Greco F. A., Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma Journal of Clinical Oncology 2002 20 20 4261 4267 (Pubitemid 35191030)
67. Hainsworth J. D., Litchy S., Shaffer D. W., Van Lackey L., Grimaldi M., Greco F. A., Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphomaa randomized phase II trial of the Minnie Pearl Cancer Research Network Journal of Clinical Oncology 2005 23 6 1088 1095 (Pubitemid 46202263)
68. Buske C., Hiddemann W., Rituximab maintenance therapy in indolent NHL: a clinical review Leukemia Research 2006 30 1 S11 S15
69. Ghielmini M., Schmitz S. F. H., Cogliatti S. B., Pichert G., Hummerjohann J., Waltzer U., Fey M. F., Betticher D. C., Martinelli G., Peccatori F., Hess U., Zucca E., Stupp R., Kovacsovics T., Helg C., Lohri A., Bargetzi M., Vorobiof D., Cerny T., Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly 4 schedule Blood 2004 103 12 4416 4423 (Pubitemid 38745964)
70. Foon K. A., Hallek M. J., Changing paradigms in the treatment of chronic lymphocytic leukemia Leukemia 2010 24 3 500 511
71. Schulz H., Klein S. K., Rehwald U., Reiser M., Hinke A., Knauf W. U., Aulitzky W. E., Hensel M., Herold M., Huhn D., Hallek M., Diehl V., Engert A., Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia Blood 2002 100 9 3115 3120 (Pubitemid 35217057)
72. Lamanna N., Kalaycio M., Maslak P., Jurcic J. G., Heaney M., Brentjens R., Zelenetz A. D., Horgan D., Gencarelli A., Panageas K. S., Scheinberg D. A., Weiss M. A., Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia Journal of Clinical Oncology 2006 24 10 1575 1581 (Pubitemid 46638781)
73. Robak T., Smolewski P., Cebula B., Grzybowska-Izydorczyk O., Boski J. Z., Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia European Journal of Haematology 2007 79 2 107 113 (Pubitemid 47063264)
74. Hallek M., Fingerle-Rowson G., Fink A.-M., First-line treatment with fludarabine (f), cyclophosphamide (c), and rituximab (r) (fcr) improves overall survival (os) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (cll): results of a randomized phase iii trial on behalf of an international group of investigators and the german cll study group Blood 2009 114
75. Keating M. J., O'Brien S., Albitar M., Lerner S., Plunkett W., Giles F., Andreeff M., Cortes J., Faderl S., Thomas D., Koller C., Wierda W., Detry M. A., Lynn A., Kantarjian H., Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia Journal of Clinical Oncology 2005 23 18 4079 4088 (Pubitemid 46211313)
76. Tam C. S., O'Brien S., Wierda W., Kantarjian H., Wen S., Do K. A., Thomas D. A., Cortes J., Lerner S., Keating M. J., Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia Blood 2008 112 4 975 980
77. Wierda W., O'Brien S., Wen S., Faderl S., Garcia-Manero G., Thomas D., Do K. A., Cortes J., Koller C., Beran M., Ferrajoli A., Giles F., Lerner S., Albitar M., Kantarjian H., Keating M., Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia Journal of Clinical Oncology 2005 23 18 4070 4078 (Pubitemid 46211312)
78. Beum P. V., Lindorfer M. A., Taylor R. P., Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving Journal of Immunology 2008 181 4 2916 2924
79. Kennedy A. D., Beum P. V., Solga M. D., DiLillo D. J., Lindorfer M. A., Hess C. E., Densmore J. J., Williams M. E., Taylor R. P., Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia Journal of Immunology 2004 172 5 3280 3288 (Pubitemid 38263720)
80. Beum P. V., Kennedy A. D., Taylor R. P., Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas Journal of Immunological Methods 2004 289 1-2 97 109 (Pubitemid 38900908)
81. Shimizu R., Kikuchi J., Wada T., Ozawa K., Kano Y., Furukawa Y., HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells Leukemia 2010 24 10 1760 1768
82. Henry C., Deschamps M., Rohrlich P. S., Pallandre J. R., Rmy-Martin J. P., Callanan M., Traverse-Glehen A., GrandClment C., Garnache-Ottou F., Gressin R., Deconinck E., Salles G., Robinet E., Tiberghien P., Borg C., Ferrand C., Identification of an alternative CD20 transcript variant in B-cell malignancies coding for a novel protein associated to rituximab resistance Blood 2010 115 12 2420 2429
83. Bhat R., Watzl C., Serial killing of tumor cells by human natural killer cellsenhancement by therapeutic antibodies PLoS ONE 2007 2 3, article no. e326
84. Bowles J. A., Weiner G. J., CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells Journal of Immunological Methods 2005 304 1-2 88 99 (Pubitemid 41262223)
85. Fischer L., Penack O., Gentilini C., Nogai A., Muessig A., Thiel E., Uharek L., The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells Experimental Hematology 2006 34 6 753 759 (Pubitemid 43737097)
86. Berdeja J. G., Hess A., Lucas D. M., O'Donnell P., Ambinder R. F., Diehl L. F., Carter-Brookins D., Newton S., Flinn I. W., Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab Clinical Cancer Research 2007 13 8 2392 2399 (Pubitemid 46698589)
87. Wang H., Liu Y., Li Z. Y., Fan X., Hemminki A., Lieber A., A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy Blood 2010 115 3 592 600
88. Sato F., Ito A., Ishida T., Mori F., Takino H., Inagaki A., Ri M., Kusumoto S., Komatsu H., Iida S., Okada N., Inagaki H., Ueda R., A complement-dependent cytotoxicity-enhancing anti-CD20 antibody mediating potent antitumor activity in the humanized NOD/Shi-scid, IL- 2Rnull mouse lymphoma model Cancer Immunology, Immunotherapy 2010 59 12 1791 1800
89. Chao M. P., Alizadeh A. A., Tang C., Myklebust J. H., Varghese B., Gill S., Jan M., Cha A. C., Chan C. K., Tan B. T., Park C. Y., Zhao F., Kohrt H. E., Malumbres R., Briones J., Gascoyne R. D., Lossos I. S., Levy R., Weissman I. L., Majeti R., Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma Cell 2010 142 5 699 713
90. Xuan C., Steward K. K., Timmerman J. M., Morrison S. L., Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma Blood 2010 115 14 2864 2871
91. Li B., Zhao L., Guo H., Wang C., Zhang X., Wu L., Chen L., Tong Q., Qian W., Wang H., Guo Y., Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma Blood 2009 114 24 5007 50515
92. Stein R., Qu Z., Chen S., Rosario A., Shi V., Hayes M., Horak I. D., Hansen H. J., Goldenberg D. M., Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma Clinical Cancer Research 2004 10 8 2868 2878 (Pubitemid 38509167)
93. Maddipatla S., Hernandez-Ilizaliturri F. J., Knight J., Czuczman M. S., Augmented antitumor activity against b-cell lymphoma by a combination of monoclonal antibodies targeting trail-r1 and cd20 Clinical Cancer Research 2007 13 15 4556 4564 (Pubitemid 47219726)
94. Tobin E., DeNardo G. L., Zhang N., Epstein A. L., Liu C., DeNardo S., Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines Leukemia and Lymphoma 2007 48 5 944 956 (Pubitemid 47161567)
95. Rossi E. A., Goldenberg D. M., Cardillo T. M., McBride W. J., Sharkey R. M., Chang C. H., Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting Proceedings of the National Academy of Sciences of the United States of America 2006 103 18 6841 6846
96. Rossi E. A., Goldenberg D. M., Cardillo T. M., Stein R., Chang C. H., Hexavalent bispecific antibodies represent a new class of anticancer therapeutics1. Properties of anti-CD20/CD22 antibodies in lymphoma Blood 2009 113 24 6161 6171
97. Rossi E. A., Goldenberg D. M., Cardillo T. M., Stein R., Wang Y., Chang C. H., Novel designs of multivalent anti-CD20 humanized antibodies as improved lymphoma therapeutics Cancer Research 2008 68 20 8384 8392
98. Gupta P., Goldenberg D. M., Rossi E. A., Chang C.-H., Multiple signaling pathways induced by hexavalent, monospecific, anti-CD20 and hexavalent, bispecific, anti-CD20/CD22 humanized antibodies correlate with enhanced toxicity to B-cell lymphomas and leukemias Blood 2010 116 17 3258 3267
99. Leonard J. P., Coleman M., Ketas J. C., Chadburn A., Ely S., Furman R. R., Wegener W. A., Hansen H. J., Ziccardi H., Eschenberg M., Gayko U., Cesano A., Goldenberg D. M., Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma Journal of Clinical Oncology 2003 21 16 3051 3059 (Pubitemid 46606284)
100. Leonard J. P., Coleman M., Ketas J. C., Chadburn A., Furman R., Schuster M. W., Feldman E. J., Ashe M., Schuster S. J., Wegener W. A., Hansen H. J., Ziccardi H., Eschenberg M., Gayko U., Fields S. Z., Cesano A., Goldenberg D. M., Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results Clinical Cancer Research 2004 10 16 5327 5334 (Pubitemid 39100467)
101. Younes A., Hariharan K., Allen R. S., Leigh B. R., Initial trials of anti-CD80 monoclonal antibody (galiximab) therapy for patients with relapsed or refractory follicular lymphoma Clinical Lymphoma 2003 3 4 257 259 (Pubitemid 36416853)
102. Vyth-Dreese F. A., Dellemijn T. A. M., Majoor D., De Jong D., Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal human lymphoid tissue European Journal of Immunology 1995 25 11 3023 3029
103. Munro J. M., Freedman A. S., Aster J. C., Gribben J. G., Lee N. C., Rhynhart K. K., Banchereau J., Nadler L. M., In vivo expression of the B7 costimulatory molecule by subsets of antigen- presenting cells and the malignant cells of Hodgkin's disease Blood 1994 83 3 793 798
104. Leonard J. P., Friedberg J. W., Younes A., Fisher D., Gordon L. I., Moore J., Czuczman M., Miller T., Stiff P., Cheson B. D., Forero-Torres A., Chieffo N., McKinney B., Finucane D., Molina A., A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma Annals of Oncology 2007 18 7 1216 1223 (Pubitemid 47244369)
105. Keating M. J., Flinn I., Jain V., Binet J. L., Hillmen P., Byrd J., Albitar M., Brettman L., Santabarbara P., Wacker B., Rai K. R., Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Blood 2002 99 10 3554 3561 (Pubitemid 34534522)
106. Lundin J., Hagberg H., Repp R., Cavallin-Sthl E., Fredn S., Juliusson G., Rosenblad E., Tjonnfjord G., Wiklund T., sterborg A., Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Szary syndrome Blood 2003 101 11 4267 4272 (Pubitemid 36857787)
107. Enblad G., Hagberg H., Erlanson M., Lundin J., MacDonald A. P., Repp R., Schetelig J., Seipelt G., sterborg A., A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy- refractory peripheral T-cell lymphomas Blood 2004 103 8 2920 2924 (Pubitemid 38451660)
108. Gallamini A., Zaja F., Patti C., Billio A., Specchia M. R., Tucci A., Levis A., Manna A., Secondo V., Rigacci L., Pinto A., Iannitto E., Zoli V., Torchio P., Pileri S., Tarella C., Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial Blood 2007 110 7 2316 2323 (Pubitemid 47523150)
109. Stein R., Qu Z., Chen S., Solis D., Hansen H. J., Goldenberg D. M., Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab Blood 2006 108 8 2736 2744
110. Hillmen P., Skotnicki A. B., Robak T., Jaksic B., Dmoszynska A., Wu J., Sirard C., Mayer J., Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia Journal of Clinical Oncology 2007 25 35 5616 5623
111. Dunleavy K., White T., Grant N., Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia 2005 23. ASCO Meeting Abstract 6607
112. DeNardo G. L., DeNardo S. J., Goldstein D. S., Kroger L. A., Lamborn K. R., Levy N. B., McGahan J. P., Salako Q., Shen S., Lewis J. P., Maximum-tolerated dose, toxicity, and efficacy of I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma Journal of Clinical Oncology 1998 16 10 3246 3256 (Pubitemid 28481618)
113. Schnell R., Dietlein M., Schomcker K., Kobe C., Borchmann P., Schicha H., Hallek M., Engert A., Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's lymphoma Onkologie 2008 31 1-2 49 51 (Pubitemid 351252941)
114. Ma D., McDevitt M. R., Barendswaard E., Lai L., Curcio M. J., Pellegrini V., Brechbiel M. W., Scheinberg D. A., Radioimmunotherapy for model B cell malignancies using Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies Leukemia 2002 16 1 60 66 (Pubitemid 34105600)
115. Witzig T. E., Gordon L. I., Cabanillas F., Czuczman M. S., Emmanouilides C., Joyce R., Pohlman B. L., Bartlett N. L., Wiseman G. A., Padre N., Grillo-Lpez A. J., Multani P., White C. A., Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma Journal of Clinical Oncology 2002 20 10 2453 2463 (Pubitemid 34525730)
116. Witzig T. E., Molina A., Gordon L. I., Emmanouilides C., Schilder R. J., Flinn I. W., Darif M., Macklis R., Vo K., Wiseman G. A., Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan Cancer 2007 109 9 1804 1810 (Pubitemid 46668544)
117. Morschhauser F., Illidge T., Huglo D., Martinelli G., Paganelli G., Zinzani P. L., Rule S., Liberati A. M., Milpied N., Hess G., Stein H., Kalmus J., Marcus R., Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation Blood 2007 110 1 54 58 (Pubitemid 47026818)
118. Zinzani P. L., Tani M., Fanti S., Stefoni V., Musuraca G., Castellucci P., Marchi E., Farsad M., Fina M., Pellegrini C., Alinari L., Derenzini E., de Vivo A., Bacci F., Pileri S., Baccarani M., A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients Annals of Oncology 2008 19 4 769 773 (Pubitemid 351461050)
119. Horning S. J., Younes A., Jain V., Kroll S., Lucas J., Podoloff D., Goris M., Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab Journal of Clinical Oncology 2005 23 4 712 719 (Pubitemid 46224170)
120. Kaminski M. S., Tuck M., Estes J., Kolstad A., Ross C. W., Zasadny K., Regan D., Kison P., Fisher S., Kroll S., Wahl R. L., 131I-tositumomab therapy as initial treatment for follicular lymphoma New England Journal of Medicine 2005 352 5 441 449 (Pubitemid 40175970)
121. Press O. W., Unger J. M., Braziel R. M., Maloney D. G., Miller T. P., LeBlanc M., Fisher R. I., Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group protocol S9911 Journal of Clinical Oncology 2006 24 25 4143 4149 (Pubitemid 46622291)
122. Gopal A. K., Pagel J. M., Fromm J. R., Wilbur S., Press O. W., 131 I anti-CD45 radioimmunotherapy effectively targets and treats T-cell non-Hodgkin lymphoma Blood 2009 113 23 5905 5910
123. Witzig T., Emmanouilides C., Molina A., Gordon L., Gaston I., Flinn I., Yttrium-90 ibritumomab tiuxetan radioimmunotherapy (RIT) induces durable complete responses (CR/CRu) in patients with relapsed or refractory B-cell non-Hodgkins lymphoma (NHL) Proceedings of the American Society of Clinical Oncology 2003 22 597
124. Kaminski M. S., Zelenetz A. D., Press O. W., Saleh M., Leonard J., Fehrenbacher L., Lister T. A., Stagg R. J., Tidmarsh G. F., Kroll S., Wahl R. L., Knox S. J., Vose J. M., Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas Journal of Clinical Oncology 2001 19 19 3918 3928 (Pubitemid 32912019)
125. Kaminski M. S., Tuck M., Estes J., Kolstad A., Ross C. W., Zasadny K., Regan D., Kison P., Fisher S., Kroll S., Wahl R. L., 131 I -tositumomab therapy as initial treatment for follicular lymphoma New England Journal of Medicine 2005 352 5 441 449 (Pubitemid 40175970)
126. Juweid M. E., Stadtmauer E., Hajjar G., Sharkey R. M., Suleiman S., Luger S., Swayne L. C., Alavi A., Goldenberg D. M., Pharmacokinetics, dosimetry, and initial therapeutic results with I- and In-/Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma Clinical Cancer Research 1999 5 10 3292s 3303s (Pubitemid 29493930)
127. ODonnell R., DeNardo G., Kukis D., 67copper-2-iminothiolane-6-[p- (bromoacetamido) benzyl]-teta-lym-1 for radioimmunotherapy of non-hodgkins lymphoma Clinical Cancer Research 1999 5 10 3330s
128. O'Donnell R. T., DeNardo G. L., Kukis D. L., Lamborn K. R., Shen S., Yuan A., Goldstein D. S., Carr C. E., Mirick G. R., DeNardo S. J., A clinical trial of radioimmunotherapy with Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma Journal of Nuclear Medicine 1999 40 12 2014 2020 (Pubitemid 30022015)
129. Aurlien E., Larsen R. H., Kvalheim G., Bruland. S., Demonstration of highly specific toxicity of the -emitting radioimmunoconjugate 211At -rituximab against non-Hodgkin's lymphoma cells British Journal of Cancer 2000 83 10 1375 1379
130. Knop S., Jakob A., Kanz L., Hebart H., Bares R., Dohmen B., 186Rhenium-labeled anti-CD20 antibody radioimmunotherapy followed by autologous peripheral blood stem cell transplantation in patients with relapsed or refractory non-Hodgkin lymphoma Blood 2004 103 3 1175 (Pubitemid 38129589)